Science News

COVID-19 Professional Resources
The AHA is working to ensure optimal care for patients with cardiovascular disease who contract coronavirus (COVID-19). Patients with underlying cardiovascular diseases appear to have an increased risk for adverse outcomes with COVID-19. Here are some helpful resources for health systems, clinics, care providers, patients and the public.
AHA Journals This Week | July 6, 2020
07/06/2020 | AHA Journals This Week July 6, 2020
ATVB | Featured Articles | June 2020
05/28/2020 | ATVB June 2020 Editor's Pick and Featured Article
Collaboration with LLNL shares COVID-19 research data
05/22/2020 | The American Heart Association is pleased to announced that our collaboration with Lawrence Livermore National Labs (LLNL) on the protein atlas developed through the AHA Center for Accelerated Discovery is being leveraged to help accelerate discovery of therapeutic antibodies or antiviral drugs for SARS-CoV-2, the virus that causes COVID-19.
AHA, ACC redefine guideline processes
04/27/2020 | In a historic move, the AHA and ACC re-visited their 30-year partnership of jointly producing clinical practice guidelines for the cardiovascular community.
CIRCULATION Editor's Picks | Feb/March 2020
03/19/2020 | CIRCULATON Editor's Picks for January 2020
HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19
03/16/2020 | Patients with underlying cardiovascular diseases appear to have an increased risk for adverse outcomes with coronavirus disease 2019 (COVID-19).
JAHA Conference Reads| EPI Lifestyle 2020
03/02/2020 | JAHA Conference Reads for EPI Lifestyle 2020
Exercise-Related Acute Cardiovascular Events & Potential Deleterious Adaptations
02/26/2020 | The benefits of regular moderate-to-vigorous physical activity (PA), and the associated improvements in cardiorespiratory fitness (CRF), far outweigh the risks for most individuals.
STROKE | Progress and Innovation Award 2019
02/12/2020 | Stroke 2019 Innovation and Progress Award Winners--first: Ma and Wang, Second: Yip, Third: Schlunk